A share that rises does not automatically become a good purchase. It becomes more expensive relative to the hypotheses that justified yesterday’s price. If those hypotheses have not improved by the same amount, the margin has narrowed.
That is why the work starts from the company: stability of the accounts, an advantage that does not depend on a single quarter, debt that does not dictate the story. The chart comes in afterwards, for the timing of the entry, not to invent the reason for the entry.
There is no intrinsic value that is true in an absolute sense. There is an estimate, with written hypotheses, and it can be wrong. The point of the method is not to be right to the cent. It is to refuse the cases in which, even on generous hypotheses, the price leaves no gap.
This is not an invitation to buy or sell a name in the public portfolio. It is the way that portfolio is explained.
Informational note. This is not a recommendation to buy or sell, nor a forecast. The returns cited are those of the public series and may change.